Clinical Trials

Inclusion Criteria:

• ≥ 18 years of age.
• New or locally recurrent diagnosis of HER2+ breast cancer that will be treated with curative intent.
• Planned HER2-directed therapy (any therapy targeting HER2 signaling including trastuzumab +/- pertuzumab or trastuzumab-emtansine (T-DM1)). Neratinib and lapatinib will not be considered “Her2-directed therapy” or “anti-HER2” for the purpose of this study.

Exclusion Criteria:

• Metastatic breast cancer (distant metastases).
• Active systemic treatment for non-breast cancer.
• History of HF of any class and type, or diagnosis of cardiomyopathy in the past, LVEF < 50% at screening, intolerance to beta-blocker, baseline use of any beta-blocker for coronary artery disease including myocardial infarction, current ACE inhibitor or ARB therapy for hypertension in the presence of diabetes and/or for chronic kidney disease/proteinuria, on active therapy with amiodarone, sotalol, or any other antiarrhythmic history of bronchial asthma or related  bronchospastic conditions, heart rate < 50 BPM at screening (average of 3 most recent readings).
• History of or current sick sinus syndrome.
• AV block grade II or higher (unless patient has a permanent pacemaker) at screening.
• Systolic blood pressure < 90 mmHg at screening (average of 3 most recent readings).
• Severe hepatic dysfunction, as defined by NCI ODWG (total bilirubin > 3x ULN with any AST elevation) or Child Pugh C class.
• Pregnancy.